Ubidecarenone (coenzyme Q10)

Other cardiac preparations. Coenzyme Q10

ATC code: C01EB-COQ10(Ubidecarenone (CoQ10) – local code)

Brand names – supplements: Nature's Bounty Co Q-10, Qunol Ultra CoQ10, Jarrow Formulas Ubiquinol QH-Absorb Supplements are not tested in clinical trials and are not registered as medications.

Updated 24 Sep 2026 · Methodology

Indications

Primary coenzyme Q10 deficiency

First line

High-dose CoQ10 (10–30 mg/kg/day, in adults up to 1,200–2,400 mg daily) is the only disease-modifying approach to the rare inherited primary CoQ10 deficiency. Early therapy in children prevents progression of encephalopathy and nephrotic syndrome; in adults it stabilises cerebellar ataxia. GeneReviews and international mitochondrial disease guidelines support this use.

Used in specialised centres with confirmed genetic diagnosis; not for self-prescription.

Sources

ICD-10: E88.4 · ICD-11: 5C53.22

Migraine prophylaxis

Adjunct

Coenzyme Q10 is considered as preventive therapy in episodic migraine, particularly in patients intolerant to topiramate, β-blockers, or amitriptyline. RCTs Sandor 2005 (n=42), Shoeibi 2017 (n=80), and the Zeng 2018 meta-analysis (5 RCTs) show 30–50% reduction in attack frequency at 300 mg/day (100 mg three times). Effect develops over 3 months. /AHS 2012 and European Headache Federation guidelines classify CoQ10 as category C («possibly effective») – an acceptable option when first-line prophylaxis is contraindicated. EHF guidelines also list CoQ10 as an option in children.

Sources

ICD-10: G43.9 · ICD-11: 8A80.Z

Heart failure

Individual decision

In chronic heart failure, coenzyme Q10 has been studied as add-on therapy to guideline-directed treatment (ACE inhibitors/ARNI, β-blockers, mineralocorticoid receptor antagonists). The Q-SYMBIO trial (Mortensen 2014, n=420, 2 years) showed 43% reduction in the composite endpoint (mortality + adverse cardiovascular events) at 300 mg/day. The result is criticized for small sample size and design issues. 2021 HF guidelines do not include CoQ10 as mandatory therapy but describe it as an «acceptable add-on option». / 2022 guidelines do not mention CoQ10.

Sources

ICD-10: I50 · ICD-11: BD10

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Statin-associated muscle symptoms

Not recommended

Coenzyme Q10 is widely used as an «antidote» to statin myalgia based on the theory of CoQ10 depletion during statin therapy. Evidence is conflicting. Banach 2015 meta-analysis (12 RCTs, n=575) showed significant muscle pain score reduction. Later and larger Taylor 2015 (5 RCTs, n=253) and Qu 2018 (12 RCTs) analyses did not confirm the effect. 2019 and / 2018 guidelines do not recommend CoQ10 as evidence-based therapy for statin myalgia; the supplement is permissible as an «option when statin switch is contraindicated» but not first-line. First-line management of statin myalgia: dose reduction, statin switch (pravastatin, fluvastatin), alternate-day dosing.

Sources

ICD-10: M62.8 · ICD-11: FB56.2

Anti-aging and longevity

Not recommended

Ubidecarenone, better known as coenzyme Q10 (CoQ10), is a compound the body makes on its own. It is sold as a supplement to slow aging and extend lifespan. For anti-aging and longevity, the supplement has not shown convincing benefit, and there is no solid evidence base for this use. For the skin, sun protection and retinoids do the work; for lifespan, sleep, not smoking, and physical activity matter most.

Sources

Cochrane: Coenzyme Q10 for heart failure (2021)

Athletic endurance

Not recommended

Ubidecarenone (coenzyme Q10) is a substance the body makes on its own; in supplements it's marketed as a way to boost athletic endurance and speed up recovery. Convincing benefit for this use hasn't been shown – there's no solid evidence that coenzyme Q10 improves endurance in healthy people. Endurance grows from regular training, enough sleep, and balanced nutrition, which are the approaches that actually deliver.

Sources

How to read tiers A–F

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit

Mechanism of action

Ubiquinone (CoQ10) is a component of the inner mitochondrial membrane electron transport chain, transferring electrons between complexes I/II and III. Required for ATP synthesis. An antioxidant: regenerates tocopherol and neutralises reactive oxygen species in membranes. Synthesised endogenously; levels decline with age and with statin therapy (via mevalonate pathway inhibition). Exists in two forms: oxidised (ubiquinone) and reduced (ubiquinol).

Safety

Contraindications

Hypersensitivity to ubiquinone
Pregnancy (insufficient data)
Breastfeeding (insufficient data)
Children under 18 (for most supplement forms)

Serious adverse effects

Serious adverse events at standard doses are not reported

Common adverse effects

Nausea, heartburn
Epigastric discomfort
Headache

Uncommon adverse effects

Allergic reactions (rash, pruritus)
Insomnia, irritability with evening high-dose use

Pregnancy: can you take Ubidecarenone (coenzyme Q10)?

Pregnancy data are limited. In planned pregnancy and breastfeeding, use is not recommended without clear clinical indication.

Breastfeeding: can you take Ubidecarenone (coenzyme Q10)?

No data on transfer into breast milk. Use during breastfeeding is not recommended.

Calculate RID Full profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Timing and administration

Take with food, preferably one containing fat – CoQ10 is fat-soluble and absorption increases 2–3 fold with dietary fat. Divide the dose into 2–3 daily portions – large single doses are absorbed less efficiently.

Dose titration

Migraine prophylaxis: 100 mg three times daily. Heart failure: 100 mg three times daily (as in Q-SYMBIO). Primary CoQ10 deficiency: 10–30 mg/kg/day. Standard supplement doses of 30–60 mg daily roughly match age-related synthesis losses but are not clinically indicated for treatment.

Russian practice note

In Russia, coenzyme Q10 is sold both as a medicinal product (Kudesan) and as a dietary supplement. Marketing doses are 60–300 mg/day (statin myalgia 100–300 mg, HF 300 mg, migraine 300 mg). Monthly cost is 800–3500 ₽. Ubiquinone (oxidized form) bioavailability is low – about 1–2%. Ubiquinol (reduced form, Kaneka QH) achieves 3–4 times higher plasma levels at the same dose. The coenzyme is fat-soluble – take with fatty food. Documented drug interactions are few, but a weak effect on INR reduction with warfarin is described (CoQ10 is structurally similar to vitamin K).

Monitoring

No specific monitoring is needed during long-term therapy. In patients on warfarin, monitor INR when starting or stopping CoQ10 – modest reduction in anticoagulant effect is possible. In insulin-dependent diabetes, monitor glycaemia in the first weeks – reduced insulin requirements have been reported.

Food and drinks

Dietary CoQ10 sources: beef heart, beef, sardines, mackerel, peanuts. Average adult dietary intake is 3–6 mg daily, 10–30 times less than RCT doses. Endogenous synthesis is the main source. In statin-treated patients, plasma CoQ10 is 30–40% lower, but the clinical impact for most patients is minor.

Common myths

Myth: “everyone over 40 needs CoQ10”. Fact: age-related CoQ10 decline is physiological without proven clinical consequences in healthy people. Prophylactic “energy” use has not shown a wellbeing effect in RCTs.

Myth: “CoQ10 must be taken with statins”. Fact: the 2018 Mayo Clinic systematic review did not confirm clinical benefit. Russian and international cardiology societies do not include CoQ10 in statin-patient management standards.

Myth: “ubiquinol is the active form, much better than ubiquinone”. Fact: the bioavailability difference between ubiquinol and ubiquinone is substantially smaller than advertised. Ubiquinol costs 2–3 times more without proven clinical advantage for most patients.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Ubidecarenone (coenzyme Q10) used for?

Ubidecarenone (coenzyme Q10) is evaluated for the following indications with varying evidence strength: Primary coenzyme Q10 deficiency (evidence tier A), Migraine prophylaxis (evidence tier B), Statin-associated muscle symptoms (evidence tier C). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Ubidecarenone (coenzyme Q10)?

Common side effects of Ubidecarenone (coenzyme Q10) (≥ 1 in 100): Nausea, heartburn, Epigastric discomfort, Headache. See the Safety section for uncommon and serious reactions.

Is Ubidecarenone (coenzyme Q10) safe during pregnancy?

Pregnancy data are limited. In planned pregnancy and breastfeeding, use is not recommended without clear clinical indication.

Is Ubidecarenone (coenzyme Q10) compatible with breastfeeding?

No data on transfer into breast milk. Use during breastfeeding is not recommended.

Who should not take Ubidecarenone (coenzyme Q10)?

Ubidecarenone (coenzyme Q10) is contraindicated in: Hypersensitivity to ubiquinone; Pregnancy (insufficient data); Breastfeeding (insufficient data); Children under 18 (for most supplement forms). Full list in the Safety section.

“everyone over 40 needs CoQ10”

age-related CoQ10 decline is physiological without proven clinical consequences in healthy people. Prophylactic “energy” use has not shown a wellbeing effect in RCTs.

“CoQ10 must be taken with statins”

the 2018 Mayo Clinic systematic review did not confirm clinical benefit. Russian and international cardiology societies do not include CoQ10 in statin-patient management standards.

“ubiquinol is the active form, much better than ubiquinone”

the bioavailability difference between ubiquinol and ubiquinone is substantially smaller than advertised. Ubiquinol costs 2–3 times more without proven clinical advantage for most patients.

Other drugs in this group

Digoxin, Disopyramide, Dofetilide, Dronedarone, Hawthorn (Crataegus monogyna / laevigata), Lidocaine, Propafenone, Flecainide